AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01396070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10.
Study NCT04460001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal
Study NCT04460001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetate
Description: intravitreal
Study NCT01561313 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
Study NCT01561313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
Study NCT04621149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorine dioxide
Description: chlorine dioxide is an antimicrobial agent used for a variety of purposes including as a water purification product, a disinfectant on food, etc.
Study NCT04621149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc acetate
Description: zinc acetate lozenges have been suggested to have antiviral properties
Study NCT04621149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: famoitidine is a histamine-2 blocker sold over the counter to reduce stomach acid
Study NCT04621149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: filtered water
Study NCT04621149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: filtered water
Study NCT04621149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactoferrin, green tea extract
Description: lactoferrin and green tea extract are dietary supplements
Study NCT01988285 — intervention group
Intervention type: OTHER
Intervention: Specimen Collection
Description: Blood collection, possible saliva collection, possible urine collection, and biopsy collection
Study NCT01988285 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
Study NCT00243438 — intervention group
Intervention type: DEVICE
Intervention: Multilink Vision™ Stent (CE-labeled)
Description: Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
Study NCT00916929 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Impedance Monitoring Feature
Description: Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
Study NCT02410564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy for insomnia (CBTI)
Description: SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
Study NCT02410564 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist control condition
Description: Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
Study NCT02053376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
Study NCT01360736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning - Military (SAFE MIL)
Description: The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
Study NCT01160822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Intra-articular injection
Study NCT01160822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to canakinumab
Description: Intra-articular injection
Study NCT01160822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to canakinumab
Description: Intra-articular injection
Study NCT01160822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Tablets for oral administration
Study NCT01160822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Naproxen
Description: Tablets for oral administration
Study NCT01160822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Naproxen
Description: Tablets for oral administration
Study NCT03037580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Sustained-release oral tablets for TID administration
Study NCT03037580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill) for TID oral administration
Study NCT01742286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via nasogastric/gastric (NG/G) tube. For patients in fasted group: 1-2 tablespoons (15-30 mL) of an appropriate food such as apple sauce or non-fat yogurt and a glass of water were allowed.~For patients in the fed cohort: LDK378 was taken with, or within 30 minutes after finishing a low-fat light snack containing 100-300 calories and 1.5-2 grams of fat.
Study NCT02400385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib 50mg/day po, 4 weeks on 2 weeks off
Study NCT02400385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 3mg/kg IV ever 2 weeks
Study NCT04121793 — intervention group
Intervention type: DEVICE
Intervention: Kinesia 360 and Smartphone sensors
Description: Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
Study NCT00870519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-123-MNI-168
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Study NCT00870519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I MNI-168
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Study NCT02052999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1%
Description: Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
Study NCT02052999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants received topical Vehicle twice daily for 8 weeks
Study NCT02052999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rozex gel 0.75%
Description: Participants received topical Rozex gel 0.75% twice daily for 8 weeks
Study NCT02665832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1351
Study NCT02665832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
Study NCT04121585 — intervention group
Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
Study NCT01708902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin2.5mg/metformin1000mg
Description: linagliptin2.5mg/metformin1000mg BID
Study NCT01708902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg
Description: linagliptin 5mg once daily
Study NCT01708902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500mg
Description: Metformin 500mg BID
Study NCT01708902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linagliptin2.5mg/metformin500mg
Description: linagliptin2.5mg/metformin500mg BID
Study NCT01708902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000mg
Description: Metformin 1000mg BID
Study NCT00499590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevasiranib
Description: Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
Study NCT00499590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
Study NCT04541771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri DSM 17938
Description: The trial group will receive their usual feeds plus daily probiotic addition 1 drop/kg/dose twice daily added in expressed breast milk/formula milk from the beginning of enteral feedings till the baby attain full feeds
Study NCT04541771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: expressed breast milk/formula milk plus normal saline drop from the beginning of enteral feedings till the baby attain full feeds
Study NCT00530816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
Study NCT04146636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: e-LIFT
Description: Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and \< 15 kPa)
Study NCT01490489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample and doppler Ultrasound of uterine arteries
Description: * 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch
Study NCT04413682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Supervised Exercise
Description: Structured Exercise Program under the supervision of Physical Therapist
Study NCT04413682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured telerehabilitation
Description: Structured Exercise Program checked and controlled through telerehabilitation
Study NCT01812278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Study NCT01812278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Study NCT02116205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTNV/PUUV DNA vaccine
Description: HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
Study NCT02116205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT02116205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System (TDS)
Description: The TDS-IM is an integrated, fully automated clinical EP system designed for delivering DNA-based vaccines and therapies to target tissues, through temporary disruption of cellular membranes via electrical pulses
Study NCT00757471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brillant Blue
Description: Membrane Peeling with Brillant Blue
Study NCT00757471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: Membrane Peeling with indocyanine Green
Study NCT02816385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade cardioplegia
Description: Injection of the cardioplegia in the coronary arteries
Study NCT02816385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Description: Injection of the cardioplegia in the venous system
Study NCT04059588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2141 V-11
Description: intratumoral injection of 2141-V11
Study NCT01079299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent, gradient, pneumatic compression device
Description: lymphedema pump provides external compression in a segmental,gradient fashion
Study NCT01079299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, gradient, pneumatic compression device
Description: lymphedema pump provides external compression in a segmental,gradient fashion
Study NCT04297527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in prone and supported with a pillow under the abdomen, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the lumbar region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.
Study NCT04297527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Extension SNAGS in prone, SNAGS in lion position and Lumbar flexion SNAGS in sitting, techniques were used. The techniques were applied in 3 sets with 10 repetitions and 60 seconds rest between sets.
Study NCT01039883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconazole tablet 400mg
Description: Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
Study NCT01039883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albaconazole 100mg capsules, then albaconazole 400mg tablet
Description: Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
Study NCT03245489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenous (IV) over 30 minutes
Study NCT03245489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg/day oral
Study NCT03245489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 81mg/day oral
Study NCT01215097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: once a day
Study NCT01215097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once a day
Study NCT02411097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve block
Description: use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
Study NCT01849731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face
Description: is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
Study NCT01849731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention plus telephone reinforcement
Description: In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
Study NCT02633696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silybin phosphatidylcholine
Study NCT02633696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Legalón SIL
Study NCT02541604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
Study NCT04216797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Tablets
Description: Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.
Study NCT00256568 — intervention group
Intervention type: BEHAVIORAL
Intervention: reporting system
Description: Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
Study NCT04752241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior Mesenteric Artery Preservation
Description: Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
Study NCT04752241 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Mesenteric Artery Ligation
Description: Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
Study NCT01989494 — intervention group
Intervention type: DEVICE
Intervention: Pedometer
Description: All groups will receive a pedometer to measure their daily steps
Study NCT03534180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03534180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study NCT03534180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04154813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
Study NCT04154813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
Study NCT04154813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy (CBT)
Description: CBT psychotherapy, once a week for three months.
Study NCT04154813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dialectical behavior therapy (DBT)
Description: DBT psychotherapy,once a week for three months.
Study NCT03220321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICN (VITA Enamic) hybrid abutment crown
Description: Hybrid ceramic
Study NCT03220321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lithium disilicate (IPS e.max) hybrid abutment crown
Description: Glass ceramic
Study NCT04288284 — intervention group
Intervention type: PROCEDURE
Intervention: Curative resection of colorectal cancer
Study NCT00746512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 15 mg
Description: Prednisone 15 mg tablets once daily for 15 days.
Study NCT00746512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Prednisone placebo tablets once daily for 15 days.
Study NCT00746512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 7.5 mg
Description: Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
Study NCT00746512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Over-Encapsulated Tablets
Description: Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
Study NCT02745080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Study NCT02745080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Study NCT02757417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluorescein
Study NCT02757417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenazopyridine